Once Medicare Stops Covering Telehealth Services, Will Teladoc Health Stock be in Trouble?

Source The Motley Fool

Key Points

  • Teladoc’s revenue and stock price soared in early pandemic days.

  • But in recent years, the company has struggled with various challenges.

  • 10 stocks we like better than Teladoc Health ›

Medicare is making a big change that will kick in at the end of the month. Through Jan. 30, Medicare will cover telehealth services, delivered to you wherever you are, including in your home. But as of the next day, coverage will end -- unless you live in a rural area and go to a medical facility for the appointment. There are a few other exceptions, but overall, Medicare is no longer broadly covering telehealth services as it did in the past.

Considering this shift, will Teladoc Health (NYSE: TDOC) stock -- a stock that's already faced significant headwinds in recent years -- be in trouble? Let's find out.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »

A doctor greets a patient during a telehealth visit.

Image source: Getty Images.

Teladoc's early pandemic successes

First, let's consider the Teladoc story over the past several years. The company soared to the forefront during early pandemic days as it offered people something they needed: the opportunity to see a doctor without going into a crowded medical office. Teladoc's revenue climbed, as did its stock price, as investors saw it as a pioneer, developing a new way to organize healthcare.

But several factors upset this potential growth story along the way. Teladoc's acquisition of Livongo added chronic conditions care strengths to the business, but the purchase was made at a time when valuations were high. Meanwhile, as medical offices reopened, Teladoc faced competition from this traditional way of seeing doctors as well as from others who had joined the telehealth space, such as tech giant Amazon. At the same time, BetterHelp, Teladoc's online mental health offering, expected to be a significant growth driver, has seen revenue decline. And all of this has resulted in overall revenue falling and failure to reach profitability.

As a result, the stock also has tumbled, dropping more than 70% over the past three years.

Teladoc's biggest customers

So, now, does this news from Medicare suggest more trouble ahead for Teladoc? Not necessarily. Though Teladoc hasn't said how much of its business comes from Medicare versus commercial customers such as employers, the latest annual report offers us a clue. Teladoc says, for its integrated care segment, its core business, "a significant portion of our revenue is derived from large enterprises, mainly health plans."

This suggests that commercial customers are the biggest contributors to Teladoc's revenue, and that means that this new shift in Medicare coverage may not greatly impact Teladoc's growth in the quarters to come.

This doesn't mean that Teladoc is out of the woods, however. Though the Medicare change is unlikely to weigh on the stock, the company is struggling to grow due to the challenges I mentioned above. And that means it still carries a good deal of risk.

Should you buy stock in Teladoc Health right now?

Before you buy stock in Teladoc Health, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Teladoc Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $461,527!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,155,666!*

Now, it’s worth noting Stock Advisor’s total average return is 950% — a market-crushing outperformance compared to 197% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of January 28, 2026.

Adria Cimino has positions in Amazon. The Motley Fool has positions in and recommends Amazon and Teladoc Health. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Dollar Slumps to Four-Year Low, Trump Still Says ‘Dollar Is Doing Great’?The U.S. dollar is facing its most aggressive sell-off in nearly four years, with the Bloomberg Dollar Spot Index dropping Tuesday to its lowest level since March 2022.Despite this, Presi
Author  TradingKey
13 hours ago
The U.S. dollar is facing its most aggressive sell-off in nearly four years, with the Bloomberg Dollar Spot Index dropping Tuesday to its lowest level since March 2022.Despite this, Presi
placeholder
Ethereum Is Already 20% Prepared for the Quantum Era, Says InterviewEthereum's drive for post-quantum security is advancing with strategic upgrades in execution, consensus, and data layers. The initiative is backed by the Ethereum Foundation's dedicated team. Ethereum aims to safeguard against future quantum threats well before they materialize.
Author  Mitrade
13 hours ago
Ethereum's drive for post-quantum security is advancing with strategic upgrades in execution, consensus, and data layers. The initiative is backed by the Ethereum Foundation's dedicated team. Ethereum aims to safeguard against future quantum threats well before they materialize.
placeholder
Top 3 Price Outlook: BTC Holds Above $89,000 as ETH Tests Resistance and XRP Stabilizes Near $1.90BTC trades near $89,300 after reclaiming $87,787 support and eyes $90,000, while ETH tests $3,017 and the $3,101 50-day EMA and XRP rebounds to $1.90 from $1.83 with $1.96 resistance and $1.77 downside risk.
Author  Mitrade
16 hours ago
BTC trades near $89,300 after reclaiming $87,787 support and eyes $90,000, while ETH tests $3,017 and the $3,101 50-day EMA and XRP rebounds to $1.90 from $1.83 with $1.96 resistance and $1.77 downside risk.
placeholder
EUR/USD weakens below 1.2000 amid rebound in US Dollar, all eyes on Fed rate decision The EUR/USD pair attracts some sellers to near 1.1990, snapping the four-day winning streak during the early European session on Wednesday. The major pair retraces from a five-year high amid renewed US Dollar (USD) demand.
Author  FXStreet
17 hours ago
The EUR/USD pair attracts some sellers to near 1.1990, snapping the four-day winning streak during the early European session on Wednesday. The major pair retraces from a five-year high amid renewed US Dollar (USD) demand.
placeholder
Standard Chartered warns that U.S. banks may lose up to $500 billion to stablecoins by 2028Standard Chartered has warned that banks in the U.S. may lose up to $500 billion to stablecoins by 2028.
Author  Cryptopolitan
17 hours ago
Standard Chartered has warned that banks in the U.S. may lose up to $500 billion to stablecoins by 2028.
goTop
quote